Search Results - "Rideout, Hardy"

Pathological roles of α-synuclein in neurological disorders by Vekrellis, Kostas, PhD, Xilouri, Maria, PhD, Emmanouilidou, Evangelia, PhD, Rideout, Hardy J, PhD, Stefanis, Leonidas, Dr

“…Summary Substantial genetic, neuropathological, and biochemical evidence implicates the presynaptic neuronal protein α-synuclein in Parkinson's disease and…”
Get full text

Neuronal death signaling pathways triggered by mutant LRRK2 by Rideout, Hardy J

“…Autosomal dominantly inherited mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease…”
Get more information

The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease by Rideout, Hardy J., Stefanis, Leonidas

“…Leucine-rich repeat kinase 2 (LRRK2) is a large, widely expressed protein of largely unknown function. Mutations in the gene encoding LRRK2 have been linked to…”
Get full text

LRRK2 Parkinson disease mutations enhance its microtubule association by Kett, Lauren R., Boassa, Daniela, Ho, Cherry Cheng-Ying, Rideout, Hardy J., Hu, Junru, Terada, Masako, Ellisman, Mark, Dauer, William T.

“…Dominant missense mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic causes of Parkinson disease (PD) and genome-wide association…”
Get full text

Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations by Melachroinou, Katerina, Leandrou, Emmanouela, Valkimadi, Polytimi-Eleni, Memou, Anna, Hadjigeorgiou, Georgios, Stefanis, Leonidas, Rideout, Hardy J

“…Despite the plethora of sequence variants in LRRK2, only a few clearly segregate with PD. Even within this group of pathogenic mutations, the phenotypic…”
Get full text

Defining (and blocking) neuronal death in Parkinson’s disease: Does it matter what we call it? by Memou, Anna, Dimitrakopoulos, Lampros, Kedariti, Maria, Kentros, Michalis, Lamprou, Andriana, Petropoulou-Vathi, Lilian, Valkimadi, Polytimi-Eleni, Rideout, Hardy J.

“…•Neuronal loss in Parkinson’s disease can take multiple forms.•Evidence of apoptotic, necroptotic, and pyroptotic signaling exists in PD.•The role of the…”
Get full text

The WD40 domain is required for LRRK2 neurotoxicity by Jorgensen, Nathan D, Peng, Yong, Ho, Cherry C-Y, Rideout, Hardy J, Petrey, Donald, Liu, Peng, Dauer, William T

“…Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson disease (PD). LRRK2 contains an "enzymatic core" composed of…”
Get full text

Nurr1: RXRα heterodimer activation as monotherapy for Parkinson’s disease by Spathis, Athanasios D., Asvos, Xenophon, Ziavra, Despina, Karampelas, Theodoros, Topouzis, Stavros, Cournia, Zoe, Qing, Xiaobing, Alexakos, Pavlos, Smits, Lisa M., Dalla, Christina, Rideout, Hardy J., Schwamborn, Jens Christian, Tamvakopoulos, Constantin, Fokas, Demosthenes, Vassilatis, Demetrios K.

“…Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DAergic) neurons in the substantia nigra and…”
Get full text

Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications? by Simone, Chiara, Ramirez, Agnese, Bucchia, Monica, Rinchetti, Paola, Rideout, Hardy, Papadimitriou, Dimitra, Re, Diane B, Corti, Stefania

“…Spinal muscular atrophy (SMA) is a genetic neurological disease that causes infant mortality; no effective therapies are currently available. SMA is due to…”
Get full text

Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson’s Disease Risk by Ré, Diane B., Rideout, Hardy J.

Get full text

The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration by Ho, Cherry Cheng-Ying, Rideout, Hardy J, Ribe, Elena, Troy, Carol M, Dauer, William T

“…Neurodegenerative illnesses such as Parkinson and Alzheimer disease are an increasingly prevalent problem in aging societies, yet no therapies exist that…”
Get full text

A motif within the armadillo repeat of Parkinson’s-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway by Antoniou, Nasia, Vlachakis, Dimitrios, Memou, Anna, Leandrou, Emmanouela, Valkimadi, Polytimi-Eleni, Melachroinou, Katerina, Re, Diane B., Przedborski, Serge, Dauer, William T., Stefanis, Leonidas, Rideout, Hardy J.

“…In experimental models, both in vivo and cellular, over-expression of Parkinson’s linked mutant leucine-rich repeat kinase 2 (LRRK2) is sufficient to induce…”
Get full text

The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease by Rideout, Hardy J., Chartier-Harlin, Marie-Christine, Fell, Matthew J., Hirst, Warren D., Huntwork-Rodriguez, Sarah, Leyns, Cheryl E. G., Mabrouk, Omar S., Taymans, Jean-Marc

“…Evidence is mounting that LRRK2 activity, particularly its kinase activity, is elevated in multiple forms of Parkinson’s disease, both idiopathic as well as…”
Get full text

Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Based Method by Melachroinou, Katerina, Kang, Min Suk, Liong, Christopher, Narayan, Sushma, Levers, Najah, Joshi, Neal, Kopil, Katie, Hutten, Samantha J., Baptista, Marco A.S., Padmanabhan, Shalini, Kang, Un Jung, Stefanis, Leonidas, Alcalay, Roy N., Rideout, Hardy J.

“…Background Leucine‐rich repeat kinase 2 kinase inhibitors are being vigorously pursued as potential therapeutic options; however, there is a critical need for…”
Get full text

The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease by Polissidis, Alexia, Petropoulou-Vathi, Lilian, Nakos-Bimpos, Modestos, Rideout, Hardy J

“…Biomarkers and disease-modifying therapies are both urgent unmet medical needs in the treatment of Parkinson's disease (PD) and must be developed concurrently…”
Get full text

Editorial: LRRK2-Fifteen Years From Cloning to the Clinic by Rideout, Hardy, Greggio, Elisa, Kortholt, Arjan, Nichols, R Jeremy

“…Along these lines, Cabezudo et al. discuss how mutant LRRK2-driven inflammation may trigger PD starting from peripheral organs such as the gut and immune…”
Get full text

Perspective on the current state of the LRRK2 field by Taymans, Jean-Marc, Fell, Matt, Greenamyre, Tim, Hirst, Warren D., Mamais, Adamantios, Padmanabhan, Shalini, Peter, Inga, Rideout, Hardy, Thaler, Avner

“…Almost 2 decades after linking LRRK2 to Parkinson’s disease, a vibrant research field has developed around the study of this gene and its protein product…”
Get full text

Longitudinal transcriptomic analysis of mouse sciatic nerve reveals pathways associated with age‐related muscle pathology by Comfort, Nicole, Gade, Meethila, Strait, Madeleine, Merwin, Samantha J., Antoniou, Daphne, Parodi, Chiara, Marcinczyk, Lina, Jean‐Francois, Lea, Bloomquist, Tessa R., Memou, Anna, Rideout, Hardy J., Corti, Stefania, Kariya, Shingo, Re, Diane B.

“…Background Sarcopenia, the age‐associated decline in skeletal muscle mass and strength, has long been considered a disease of muscle only, but accumulating…”
Get full text

Involvement of macroautophagy in the dissolution of neuronal inclusions by Rideout, Hardy J., Lang-Rollin, Isabelle, Stefanis, Leonidas

“…Ubiquitinated inclusions are a common feature of many neurodegenerative conditions. We have proposed that, at least in part, such inclusions may be formed due…”
Get full text

Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts by Petropoulou-Vathi, Lilian, Simitsi, Athina, Valkimadi, Politymi-Eleni, Kedariti, Maria, Dimitrakopoulos, Lampros, Koros, Christos, Papadimitriou, Dimitra, Papadimitriou, Alexandros, Stefanis, Leonidas, Alcalay, Roy N., Rideout, Hardy J.

“…Despite several advances in the field, pharmacodynamic outcome measures reflective of LRRK2 kinase activity in clinical biofluids remain urgently needed. A…”
Get full text